JP2014503206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503206A5 JP2014503206A5 JP2013544747A JP2013544747A JP2014503206A5 JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- adenoviral
- adenoviral vector
- vector
- antigen protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 22
- 241000711950 Filoviridae Species 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 108090000565 Capsid Proteins Proteins 0.000 claims 4
- 102100023321 Ceruloplasmin Human genes 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 241001115402 Ebolavirus Species 0.000 claims 3
- 241000894007 species Species 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42295410P | 2010-12-14 | 2010-12-14 | |
| US61/422,954 | 2010-12-14 | ||
| PCT/US2011/064944 WO2012082918A1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206679A Division JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503206A JP2014503206A (ja) | 2014-02-13 |
| JP2014503206A5 true JP2014503206A5 (enExample) | 2015-01-29 |
| JP6054876B2 JP6054876B2 (ja) | 2016-12-27 |
Family
ID=46245095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013544747A Active JP6054876B2 (ja) | 2010-12-14 | 2011-12-14 | アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン |
| JP2016206679A Active JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206679A Active JP6268258B2 (ja) | 2010-12-14 | 2016-10-21 | アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9701718B2 (enExample) |
| EP (1) | EP2655604B1 (enExample) |
| JP (2) | JP6054876B2 (enExample) |
| KR (1) | KR101879892B1 (enExample) |
| CN (1) | CN103370411B (enExample) |
| AU (1) | AU2011343798B2 (enExample) |
| BR (1) | BR112013014712B1 (enExample) |
| CA (1) | CA2821289C (enExample) |
| DK (1) | DK2655604T3 (enExample) |
| EA (1) | EA029504B1 (enExample) |
| ES (1) | ES2676196T3 (enExample) |
| PL (1) | PL2655604T3 (enExample) |
| WO (1) | WO2012082918A1 (enExample) |
| ZA (1) | ZA201304260B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701718B2 (en) | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| EA035530B1 (ru) | 2014-06-26 | 2020-06-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| JP6462861B2 (ja) | 2014-09-03 | 2019-01-30 | バヴァリアン ノルディック エー／エス | フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物 |
| KR20190062617A (ko) | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| DK3197489T3 (da) | 2014-09-26 | 2021-04-19 | Beth Israel Deaconess Medical Ct Inc | Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion |
| SI3271729T1 (sl) | 2015-03-18 | 2021-04-30 | Janssen Vaccines & Prevention B.V. | Testi za rekombinantne ekspresijske sisteme |
| MA55825A (fr) | 2015-12-15 | 2022-03-09 | Janssen Vaccines & Prevention Bv | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
| MX2018009997A (es) | 2016-02-18 | 2019-02-07 | Int Flavors & Fragrances Inc | Composiciones de cápsulas de poliurea. |
| EP3429740B1 (en) | 2016-03-18 | 2021-05-05 | International Flavors & Fragrances Inc. | Silica microcapsules and methods of preparing same |
| BR112018075785A2 (pt) | 2016-06-16 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | formulação de vacina para o hiv |
| WO2018006089A1 (en) | 2016-07-01 | 2018-01-04 | International Flavors & Fragrances Inc. | Stable microcapsule compositions |
| WO2018011198A1 (en) | 2016-07-15 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| CN116764558A (zh) | 2016-09-16 | 2023-09-19 | 国际香料和香精公司 | 用粘度控制剂稳定的微胶囊组合物 |
| US20180085291A1 (en) | 2016-09-28 | 2018-03-29 | International Flavors & Fragrances Inc. | Microcapsule compositions containing amino silicone |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| US20180346648A1 (en) | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
| CA3066573A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| WO2019018724A1 (en) | 2017-07-21 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS |
| SG11202000019RA (en) * | 2017-07-28 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Methods and compositions for heterologous reprna immunizations |
| US10864263B2 (en) | 2017-11-20 | 2020-12-15 | Janssen Pharmaceuticals, Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
| SG11202005710YA (en) | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| WO2019210125A1 (en) | 2018-04-27 | 2019-10-31 | International Flavors & Fragrances Inc. | Stable polyurea microcapsule compositions |
| US11713469B2 (en) | 2018-07-20 | 2023-08-01 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing Zika antigen with improved productivity |
| WO2020064621A1 (en) | 2018-09-25 | 2020-04-02 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| WO2020131956A1 (en) | 2018-12-18 | 2020-06-25 | International Flavors & Fragrances Inc. | Hydroxyethyl cellulose microcapsules |
| BR112021022528A2 (pt) | 2019-05-14 | 2021-12-28 | Janssen Biotech Inc | Remoção eficiente de impurezas usando um processo de diafiltração |
| EP4097122A4 (en) | 2020-01-31 | 2024-07-17 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES |
| EP4150061A1 (en) | 2020-05-11 | 2023-03-22 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| KR20230028517A (ko) | 2020-06-29 | 2023-02-28 | 얀센 백신스 앤드 프리벤션 비.브이. | 호흡기 세포융합 바이러스 감염에 대한 백신 조합물 |
| AU2021303722A1 (en) | 2020-07-06 | 2022-12-15 | Janssen Pharmaceuticals, Inc. | Stabilized Corona virus spike protein fusion proteins |
| WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| CN114845733A (zh) * | 2020-08-22 | 2022-08-02 | 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” | 抗严重急性呼吸综合征病毒SARS-CoV-2的表达载体 |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| AU2022221983A1 (en) | 2021-02-19 | 2023-08-17 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| EP4124383A1 (en) | 2021-07-27 | 2023-02-01 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4154974A1 (en) | 2021-09-23 | 2023-03-29 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| EP4590689A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| CN120344553A (zh) | 2022-10-06 | 2025-07-18 | Msd国际商务股份有限公司 | 稳定的融合前piv3 f蛋白 |
| EP4406641A1 (en) | 2023-01-26 | 2024-07-31 | International Flavors & Fragrances Inc. | Biodegradable microcapsules containing low log p fragrance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852324B1 (en) * | 1997-12-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunization for ebola virus infection |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| CA2776272C (en) | 2001-10-01 | 2016-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| AU2003288273A1 (en) * | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| DK1654370T3 (en) * | 2003-08-01 | 2018-08-20 | Government Of The Us Secretary Department Of Health And Human Services | ACCELERATED EBOLA VACCINATION |
| WO2006037038A1 (en) | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| CN101072879B (zh) * | 2004-10-13 | 2011-05-11 | 克鲁塞尔荷兰公司 | 改良的腺病毒载体及其应用 |
| SI1802336T1 (sl) * | 2004-10-14 | 2012-01-31 | Crucell Holland Bv | Začetna/obnovitvena cepiva proti malariji |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| US9701718B2 (en) | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
-
2011
- 2011-12-14 US US13/994,532 patent/US9701718B2/en active Active
- 2011-12-14 AU AU2011343798A patent/AU2011343798B2/en not_active Ceased
- 2011-12-14 EA EA201390866A patent/EA029504B1/ru not_active IP Right Cessation
- 2011-12-14 EP EP11849865.8A patent/EP2655604B1/en active Active
- 2011-12-14 DK DK11849865.8T patent/DK2655604T3/en active
- 2011-12-14 JP JP2013544747A patent/JP6054876B2/ja active Active
- 2011-12-14 ES ES11849865.8T patent/ES2676196T3/es active Active
- 2011-12-14 CN CN201180067429.7A patent/CN103370411B/zh active Active
- 2011-12-14 BR BR112013014712-1A patent/BR112013014712B1/pt not_active IP Right Cessation
- 2011-12-14 CA CA2821289A patent/CA2821289C/en active Active
- 2011-12-14 KR KR1020137016833A patent/KR101879892B1/ko not_active Expired - Fee Related
- 2011-12-14 PL PL11849865T patent/PL2655604T3/pl unknown
- 2011-12-14 WO PCT/US2011/064944 patent/WO2012082918A1/en not_active Ceased
-
2013
- 2013-06-10 ZA ZA2013/04260A patent/ZA201304260B/en unknown
-
2016
- 2016-10-21 JP JP2016206679A patent/JP6268258B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503206A5 (enExample) | ||
| Martin et al. | TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice | |
| Fausther-Bovendo et al. | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? | |
| JP2020528911A5 (enExample) | ||
| JP2016506416A5 (enExample) | ||
| JP2014502156A5 (enExample) | ||
| JP2016510989A5 (enExample) | ||
| RU2015135890A (ru) | Композиция вакцины | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| JP2011530309A5 (enExample) | ||
| JP2005523318A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| JP2014516536A5 (enExample) | ||
| JP2013507907A5 (enExample) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2016534034A5 (enExample) | ||
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| JP2015057052A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| JP2016513115A5 (enExample) | ||
| JP2015524422A5 (enExample) | ||
| WO2006063101A3 (en) | Vaccines for the rapid response to pandemic avian influenza | |
| JP2019519252A5 (enExample) |